Welcome to our dedicated page for Bitwise MARA Option Income Strategy ETF news (Ticker: IMRA), a resource for investors and traders seeking the latest updates and insights on Bitwise MARA Option Income Strategy ETF stock.
The IMRA news page on Stock Titan brings together historical and contextual information related to the IMRA ticker, which appears both as Bitwise MARA Option Income Strategy ETF and as the former Nasdaq symbol for Imara Inc. For users researching this symbol, the news record is particularly important because it documents how the biopharmaceutical business once associated with IMRA evolved through a merger into Enliven Therapeutics, Inc., now trading under the ticker ELVN.
Historical news releases describe Imara as a clinical-stage biotechnology company focused on rare inherited genetic disorders of hemoglobin and other serious diseases. These communications include updates on clinical and preclinical work with tovinontrine (IMR-687), a PDE9 inhibitor in Phase 2b trials for sickle cell disease and beta-thalassemia and in development for heart failure with preserved ejection fraction, as well as IMR-261, an oral Nrf2 activator. They also include trial readouts, interim analyses, and regulatory milestones such as FDA clearance of an investigational new drug application.
Later news items detail the merger agreement between Imara and Enliven Therapeutics, Inc., an all-stock transaction that led to the combined company being renamed Enliven Therapeutics, Inc. and trading on the Nasdaq Global Select Market under the ticker ELVN. These announcements explain that, after closing, the combined company would focus on Enliven’s precision oncology programs, including small molecule kinase inhibitors for cancer.
By reviewing the IMRA news archive, readers can trace the historical trajectory of the symbol from its use for Imara’s biotechnology activities to the merger with Enliven and the subsequent ELVN listing. This context can be useful for understanding legacy references to IMRA in older news reports and how they relate to the current Enliven Therapeutics, Inc. trading under ELVN, alongside the separate identification of IMRA as Bitwise MARA Option Income Strategy ETF.
Imara Inc. (Nasdaq: IMRA) will host a conference call on August 6, 2021, at 8:30 a.m. ET to discuss its Q2 2021 financial results and recent business updates. The call can be accessed domestically at 1 (833) 519-1307 or internationally at +1 (914) 800-3873 with conference ID 6499377. Imara is focused on developing IMR-687, a potential treatment for sickle cell disease and beta-thalassemia. The drug is a selective inhibitor of PDE9 and aims to provide a multimodal mechanism of action, improving patient outcomes.
Imara Inc. (Nasdaq: IMRA) announced its public offering of shares at $6.00 each, raising gross proceeds of $50 million before expenses. The offering, expected to close on July 16, 2021, will allow the company to further develop its therapeutics for rare genetic disorders. Underwriters have a 30-day option to purchase an additional $7.5 million in shares. The shares are being offered under a previously filed shelf registration statement with the SEC.
Imara Inc. (Nasdaq: IMRA) announced a proposed underwritten public offering of $50 million of common stock, all offered by the Company. The offering is subject to market conditions, with a potential additional $7.5 million option for underwriters. This move follows a shelf registration statement filed on April 1, 2021. Imara is focused on developing therapies for rare genetic hemoglobin disorders, including its lead drug candidate, IMR-687, for sickle cell disease and beta-thalassemia. The timing and terms of the offering remain uncertain.
Imara Inc. has elected Dr. Laura A. Williams to its Board of Directors, bringing over 25 years of drug development and patient advocacy experience. Dr. Williams, currently the Senior VP at Ardelyx, is noted for her leadership in clinical trials and commitment to patient needs. Her expertise is expected to greatly aid Imara in advancing its lead therapeutic, IMR-687, for treating sickle cell disease and beta-thalassemia. The announcement follows the departure of Mette Kirstine Agger from the Board after five years.
Imara has expanded its Real Impact community support initiative, awarding 30 grants totaling $150,000 to nonprofit organizations assisting patients with sickle cell disease and beta-thalassemia. This year’s funding increased by $25,000 from 2020. The grants, assessed by external reviewers, will impact 16 states and focus on social determinants of health, virtual programming, and capacity enhancement for organizations. The initiative aims to improve the lives of affected individuals and their families by supporting local community organizations.
Imara Inc. announced positive final findings from its 93-patient Phase 2a clinical trial of IMR-687 for sickle cell disease (SCD), showing a 40% reduction in annualized vaso-occlusive crises (VOCs) compared to placebo. The study highlighted a significant increase in the time to first VOC (169 days vs 87 days) and improved patient-reported pain severity. Interim data from the open-label extension trial demonstrated sustained lower VOC rates and increased fetal hemoglobin (HbF) responses over eight months. IMR-687 was well-tolerated, paving the way for further trials, including the ongoing Ardent Phase 2b.
Imara Inc. (Nasdaq: IMRA) announces the presentation of final results from its 93-patient Phase 2a trial and interim data from the open-label extension trial for IMR-687, aimed at treating sickle cell disease. The results will be shared at the EHA Annual Congress from June 9-17, 2021. IMR-687 was shown to be well tolerated, with promising reductions in vaso-occlusive crises rates and increases in fetal hemoglobin levels. A conference call is scheduled for June 11, 2021, to discuss the findings further.
Imara Inc. (Nasdaq: IMRA) reported Q1 2021 financial results and highlighted progress in clinical trials for sickle cell disease and beta-thalassemia. The company completed enrollment for the transfusion-dependent arm of the Forte Phase 2b trial and opened higher dose arms for both Ardent and Forte trials. Cash reserves stand at $75.6 million. Q1 net loss was $10.3 million, down from $15.1 million a year ago. The firm expects R&D expenses between $50 million and $55 million for 2021. Interim analyses for the clinical trials are anticipated in H2 2021.
Imara Inc. (Nasdaq: IMRA) will host a conference call on May 11, 2021, at 8:30 a.m. ET to discuss its Q1 2021 financial results and recent business highlights. The call will be accessible through a live webcast on the company’s website. Imara is focused on developing therapies for rare genetic disorders affecting hemoglobin, with its lead candidate, IMR-687, targeting conditions such as sickle cell disease and beta-thalassemia. IMR-687 is a potent oral treatment designed to modify disease mechanisms.
Summary not available.
FAQ
What is the current stock price of Bitwise MARA Option Income Strategy ETF (IMRA)?
